MajorDirect thrombin inhibitor×Reversible P2Y12 receptor inhibitor
Updated · Methodology
Mechanism
Dabigatran is a direct reversible thrombin inhibitor. Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation (dabigatran and ticagrelor summaries of product characteristics, SmPCs, European Medicines Agency, EMA). Antiplatelet drugs increase the risk of bleeding with dabigatran (dabigatran SmPC, EMA). Ticagrelor inhibits P-glycoprotein (P-gp), the transporter that eliminates dabigatran. A 180 mg ticagrelor loading dose taken at the same time as dabigatran 110 mg increased dabigatran AUC 1.49-fold and Cmax 1.65-fold, and the 90 mg twice-daily maintenance dose increased them 1.26-fold and 1.29-fold (EMA). When the loading dose was given 2 hours after dabigatran, the increase fell to 1.27-fold and 1.23-fold (EMA).
Symptoms
The risk of overt or occult bleeding in any tissue or organ rises, up to fatal bleeding. With long-term dabigatran, mucosal bleeding, such as gastrointestinal and genitourinary bleeding, is seen more often (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath and unexplained shock (EMA). The risk is higher in moderate renal impairment and with concomitant drugs that affect haemostasis or inhibit P-glycoprotein (EMA).
Management
Antiplatelet drugs significantly increase the risk of major bleeding. Carefully assess benefit and risk before combining the drugs, and give dabigatran only if the benefit outweighs the bleeding risk (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). There is no or only limited experience with dabigatran and ticagrelor (EMA). In patients with atrial fibrillation who undergo percutaneous coronary intervention with stenting, dabigatran can be combined with antiplatelet drugs once haemostasis is achieved (EMA). Give the ticagrelor loading dose 2 hours after dabigatran (dabigatran SmPC, EMA; European Heart Rhythm Association practical guide, EHRA 2021). Ticagrelor is one of the factors that raise dabigatran levels and the bleeding risk, so watch closely for signs of bleeding or anaemia throughout treatment, especially when risk factors combine. Look for a bleeding site if haemoglobin, haematocrit or blood pressure falls without explanation (EMA). Use ticagrelor with caution in patients who take oral anticoagulants within 24 hours of a ticagrelor dose (ticagrelor SmPC, EMA). According to the US dabigatran label, ticagrelor does not require a dabigatran dose adjustment. When dabigatran is used to treat or prevent deep vein thrombosis and pulmonary embolism in adults with creatinine clearance below 50 mL/min, avoid P-glycoprotein inhibitors (dabigatran prescribing information, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pradaxa (dabigatran etexilate) capsules prescribing information (2025)– FDA label, DailyMed setid ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, sections 2.2, 5.5, 7.1–7.3, figure 3.1
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Ticagrelor (EU/1/10/655), secciones 4.4 y 4.5 (2026)– EMA, ficha técnica de Brilique (EU/1/10/655) en CIMA, nº registro 10655004, texto vigente en CIMA a 03/10/2026, sin fecha de revisión, secciones 4.4 y 4.5
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.5 (2026)– EMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442011, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 (tabla 4), 4.5 (tabla 8) y 4.8
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.4 (2026)– EMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442011, consultada 02.11.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4 (tabla 4 y evaluación beneficio-riesgo), 4.5 (tablas 8 y 9) y 4.8